AI-generated summary
The authors report on 27 participants with early-stage dry age-related macular degeneration who received multiwavelength light therapy (590, 660 and 850 nm) in single or repeated treatment series over up to 16 months. They report improvements in visual acuity, contrast sensitivity and electroretinography measures, with no significant visual decline or signs of phototoxicity. The authors note that effects in early-stage patients may be less robust because starting vision was relatively preserved.
- Participants
- 27
- Who or what was studied
- Participants with early-stage nonexudative (dry) age-related macular degeneration; 41 eyes from 27 participants, mostly female (81.5%), mean 5.6 years since diagnosis.
- Wavelengths
- 590, 660, 850 nm
- Limits stated in the abstract
- The abstract does not describe a control group, and the authors note that early-stage populations may not show robust magnitude effects.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Age-related macular degeneration, Photobiomodulation. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.